Drug Delivery Most Volatile: Delcath Systems (NASDAQ:DCTH), Bio-Path Holdings (NASDAQ:BPTH), Flamel Technologies (NASDAQ:FLML), Adamis Pharmaceuticals (NASDAQ:ADMP)

Wall Street flees from troubled Delcath Systems Inc. (NASDAQ:DCTH) after the cancer-treatment devices maker proceeds with a 1-to-16 reverse stock split. Delcath Systems, Inc. (NASDAQ:DCTH) stock performance was -20.30% in last session and finished the day at $3.73. Traded volume was 1.19million shares in the last session and the average volume of the stock remained 302.19K shares. The beta of the stock remained 2.55. Delcath Systems, Inc. (NASDAQ:DCTH) insider ownership is 0.10%.

Zacks restated their outperform rating on shares of Bio-Path Holdings Inc (NASDAQ:BPTH) in a report issued on Thursday, Analyst Ratings Network.com reports. They currently have a $7.00 target price on the stock. Zacks’ analyst wrote, “Bio-Path Holdings Inc (NASDAQ:BPTH) recently reported encouraging interim Phase I results of its lead drug candidate Liposomal Grb-2, which is well tolerated and has possible anti-leukemia benefits. Bio-Path Holdings Inc (NASDAQ:BPTH) rose 9.36 percent to $2.57 Wednesday on volume of 208.7K shares. The intra-day range of the stock was $2.29 to $2.59. Bio-Path Holdings Inc (NASDAQ:BPTH) has a market capitalization of $229.34million.

Summer Street started coverage on shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML). They issued a buy rating and a $25.00 target price on the stock. Flamel Technologies S.A. (ADR) (NASDAQ:FLML)’s stock on Apr 09, 2014 reported a increase of 9.80% to the closing price of $14.45. Its fifty two weeks range is $4.10 -$14.95. The total market capitalization recorded $367.25million. The overall volume in the last trading session was 427.1K shares. In its share capital, FLML has 25.47million outstanding shares.

Back on December 13th, Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced a simultaneous reverse split, capital raise at $5.95 along with an uplisting to Nasdaq. CRT Capital was the sole book-running manager for the offering and according to Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s Director of Investor Relations & Corporate Communications, Mark Flather, there were 27 institutions that participated. On Wednesday, shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) advanced 6.00% to close the day at $5.83. Company monthly performance is recorded as -7.17%. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) quarterly revenue growth is -6.42%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone